French ENT Society (SFORL) guidelines for the management of immunodeficient patients with head and neck cancer of cutaneous origin
C. Béjar(Assistance Publique – Hôpitaux de Paris), E. Maubec(Inserm), Claire Fieschi(Délégation Paris 7), G. Lamas(Sorbonne Université), Célèste Lebbé(Inserm), C. Françès(Navarre Institute of Health Research), M.N. Peraldi(Hôpital Saint-Louis), Nicole Basset‐Séguin(Université Paris Cité), Fréderic Faure(Fidal), J. Roux(Assistance Publique – Hôpitaux de Paris), Clemence Guenne(Hôpital Edouard Herriot)
European Annals of Otorhinolaryngology Head and Neck Diseases
March 22, 2014
Cited by 13
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k